Zobrazeno 1 - 10
of 86
pro vyhledávání: '"V. Kapp"'
Autor:
Josep Tabernero, Andrea Pirzkall, Elicia M. Penuel, William D. Hanley, Bruce B. McCall, Roxana I. Sufan, Amy V. Kapp, Manuel Hidalgo, Andrew L. Coveler, John Bridgewater, Maria Di Bartolomeo, Mark Jeffery, Alessio Amatu, Meinolf Karthaus, Vinod Ganju, Leslie Samuel, Pilar Garcia Alfonso, Christopher Jackson, Matthew E. Burge, Michael P. Findlay, Andrew G. Hill
Supplemental tables and figures Supplemental Table 1. Study drug exposure. Supplemental Table 2. Select AEs at relatively high frequency led to disproportionately more frequent irinotecan/5-FU dose changes (reduced, interrupted, or withdrawn) on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ac160f71779429f6724ad8a85eb62a8
https://doi.org/10.1158/1078-0432.22464057.v1
https://doi.org/10.1158/1078-0432.22464057.v1
Autor:
Josep Tabernero, Andrea Pirzkall, Elicia M. Penuel, William D. Hanley, Bruce B. McCall, Roxana I. Sufan, Amy V. Kapp, Manuel Hidalgo, Andrew L. Coveler, John Bridgewater, Maria Di Bartolomeo, Mark Jeffery, Alessio Amatu, Meinolf Karthaus, Vinod Ganju, Leslie Samuel, Pilar Garcia Alfonso, Christopher Jackson, Matthew E. Burge, Michael P. Findlay, Andrew G. Hill
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3.Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02b2afd34122ac04cb6d26c767b34213
https://doi.org/10.1158/1078-0432.c.6525606
https://doi.org/10.1158/1078-0432.c.6525606
Autor:
Jérôme FAYETTE, Lori Wirth, Cristina Oprean, Anghel Udrea, Antonio Jimeno, Danny Rischin, Christopher Nutting, Paul M. Harari, Tibor Csoszi, Dana Cernea, Paul O’Brien, William D. Hanley, Amy V. Kapp, Maria Anderson, Elicia Penuel, Bruce McCall, Andrea Pirzkall, Jan Baptist Vermorken
Publikováno v:
Frontiers in Oncology, Vol 6 (2016)
Background: Duligotuzumab, a novel dual-action humanized IgG1 antibody that blocks ligand binding to EGFR and HER3, inhibits signaling from all ligand-dependent HER dimers, and can elicit antibody dependent cell mediated cytotoxicity. High tumor-expr
Externí odkaz:
https://doaj.org/article/d89afeed3e904b81a4584162cf8e5c84
Autor:
Cristina Saura, Mafalda Oliveira, Valentina Gambardella, Kevin Kalinsky, Andrés Cervantes, Naoki Kotani, Ian E. Krop, Zachary William Neil Veitch, Komal Jhaveri, Dejan Juric, Erika Hamilton, Antoine Italiano, Anjali Vaze, Stephanie Royer-Joo, Katie Hutchinson, Peter Schmid, Philippe L. Bedard, Jennifer L. Schutzman, Nicholas C. Turner, Andrea Varga, Amy V. Kapp, Leslie J. Dickmann
Publikováno v:
Cancer Research. 80:P1-19
Background: Dysregulation of the PI3K/AKT/mTOR signaling pathway occurs in solid tumor malignancies. GDC-0077 (G) is a potent p110α-selective, p110α-mutant degrading inhibitor with anti-tumor activity in PIK3CA-mutant breast cancer xenograft models
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2b3a627abc0931cc93a4db286d0dffb
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-46
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-46
Autor:
Erika Hamilton, Mafalda Oliveira, Andrés Cervantes, Amy V. Kapp, Jennifer L. Schutzman, Nicholas C. Turner, Naoki Kotani, Zachary William Neil Veitch, Ian E. Krop, Dejan Juric, Antoine Italiano, Stephanie Royer-Joo, Komal Jhaveri, Philippe L. Bedard, Anjali Vaze, Peter Schmid, Katie Hutchinson, Kevin Kalinsky, Leslie J. Dickmann, Jill Fredrickson, Andrea Varga, Valentina Gambardella, Cristina Saura
Publikováno v:
Cancer Research. 80:OT1-08
Background: Activating mutations in PIK3CA, encoding the p110α subunit of phosphatidylinositol 3-kinase (PI3K), are highly prevalent in breast cancer and solid tumor malignancies. GDC-0077 is a potent p110α-selective inhibitor with a novel mechanis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc5bf22ca7934f0794876215f24e77b3
https://doi.org/10.1158/1538-7445.sabcs19-ot1-08-04
https://doi.org/10.1158/1538-7445.sabcs19-ot1-08-04
Autor:
Vinod Ganju, M. Karthaus, Alessio Amatu, Andrea Pirzkall, Amy V. Kapp, Michael Findlay, Maria Di Bartolomeo, Leslie Samuel, Manuel Hidalgo, Bruce McCall, Christopher Jackson, Roxana Ioana Sufan, Andrew L. Coveler, William D. Hanley, John Bridgewater, Matthew Burge, Elicia Penuel, Pilar García Alfonso, Andrew G. Hill, Josep Tabernero, Mark Jeffery
Publikováno v:
Clinical Cancer Research. 24:2276-2284
Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI until progression or intolerabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccae888b9f36e880f1895c859efd2c58
https://doi.org/10.1158/1078-0432.ccr-17-0646
https://doi.org/10.1158/1078-0432.ccr-17-0646
Autor:
Marcos Vinicius Silva Oliveira, Amy V. Kapp, Wai Y. Chan, Steven Gendreau, Stina M. Singel, S-B Kim, Matthew Wongchenko, Rebecca Dent, Cristina Saura, Daniel J. Maslyar, J. Baselga
Publikováno v:
Cancer Research. 78:P2-09
Background: The oral Akt inhibitor IPAT is being evaluated in cancers with a high prevalence of PI3K/Akt pathway activation. In the placebo-controlled randomized phase II LOTUS trial (NCT02162719), adding IPAT to PAC as first-line therapy for metasta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e760b20a9714ef4d06fc480c75fb365
https://doi.org/10.1158/1538-7445.sabcs17-p2-09-20
https://doi.org/10.1158/1538-7445.sabcs17-p2-09-20
Autor:
Polina V. Kapp
Publikováno v:
Urban construction and architecture. 6:103-108
The article views topical questions affecting different modern forming methods in effective marketing and architectural strategy of multifunctional shopping mall. The emphasis is put on transformation aspects of functionality of shopping malls in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b5a079490cdfe9114bed10b6c7577a63
https://doi.org/10.17673/vestnik.2016.03.17
https://doi.org/10.17673/vestnik.2016.03.17
Autor:
Amy V. Kapp, Stephanie Royer-Joo, Lori J. Wirth, Antonio Jimeno, X. Wang, Tanguy Y. Seiwert, Jean-Pascal Machiels, Bruce McCall, Pol Specenier, Feby Mardjuadi, Elicia Penuel, Paul Clement, Andrea Pirzkall
Publikováno v:
Cancer. 122:3803-3811
BACKGROUND This open-label, multicenter, phase Ib study assessed the safety and preliminary activity of duligotuzumab, a dual-action antibody that blocks ligand binding to human epidermal growth factor receptor 3 (HER3) and epidermal growth factor re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97ef0b534bb09f451e0370104e1f425f
https://doi.org/10.1002/cncr.30256
https://doi.org/10.1002/cncr.30256
Autor:
Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko, Amy V Kapp, Wai Y Chan, Stina M Singel, Daniel J Maslyar, José Baselga, Keun Seok Lee, Hwei-Chung Wang, Antoinette Tan, Joo Hyuk Sohn, Michelino De Laurentiis, Laura Garcia Estevez, Chiun-Sheng Huang, Gilles Romieu, Michel Velez, Rafael Villanueva, Pier Franco Conte, Shaker Dakhil, Marc Debled, Antonio Gonzalez Martin, Sara Hurvitz, Jee Hyun Kim, Christelle Levy, Pedro Sanchez Rovira, Jae Hong Seo, Vicente Valero, Gregory Vidal, Andrea Wong, Mary Ann K Allison, Robert Figlin, David Chan, Shin-Cheh Chen, Yen-Hsun Chen, Melody Cobleigh, Filippo De Braud, Luc Dirix, Vincent Hansen, Anne Hardy Bessard, Nicholas Iannotti, Steven Isakoff, William Lawler, Alvaro Montaño, Mohamad Salkini, Leonard Seigel
Publikováno v:
The Lancet. Oncology, vol 18, iss 10
Summary Background The oral AKT inhibitor ipatasertib is being investigated in cancers with a high prevalence of PI3K/AKT pathway activation, including triple-negative breast cancer. The LOTUS trial investigated the addition of ipatasertib to paclita
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23bb66843d8ecfd467caeec1baf17b8a
https://escholarship.org/uc/item/7z70q2hf
https://escholarship.org/uc/item/7z70q2hf